How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.

Thrombopoietin receptor agonists effectively manage chemotherapy-induced thrombocytopenia, improving patient outcomes in 4 illustrative clinical cases.

• Why it matters: CIT poses significant risks like bleeding and reduced chemotherapy efficacy, yet no licensed therapies are widely available, creating a critical treatment gap for affected patients.
• What they did: The authors reviewed clinical trials and real-world cases, focusing on the use of TPO-RAs such as romiplostim and avatrombopag, to develop detailed management strategies.
• The result: Proper application of TPO-RAs, including patient selection and dosing, can optimize CIT treatment, reduce complications, and support continued cancer therapy.